Business

Indian Pharma Giants Turn to Acquisitions as Cash Reserves Soar to Rs. 49,000 Crore

This unprecedented liquidity is fuelling a fresh wave of overseas acquisitions, forays into advanced therapies, and the creation of financial cushions to navigate regulatory and trade challenges—particularly in the US, which remains India’s most critical pharmaceutical export market, contributing nearly 30% of its annual pharma exports valued at around ?2.5 trillion.

• By Newsdesk
• New Delhi
• Jun 18, 2025

Business

India's top pharmaceutical companies are sitting on a record cash pile of ₹48,913 crore as of March 31, more than double the ₹22,240 crore held in FY20, according to data analysed by Moneycontrol. The 20 firms that comprise the Nifty Pharma Index added over ₹10,200 crore in the current financial year alone, highlighting a strategic shift in capital allocation.

This unprecedented liquidity is fuelling a fresh wave of overseas acquisitions, forays into advanced therapies, and the creation of financial cushions to navigate regulatory and trade challenges—particularly in the US, which remains India’s most critical pharmaceutical export market, contributing nearly 30% of its annual pharma exports valued at around ₹2.5 trillion.

M&A Becomes a Core Growth Strategy

India’s pharmaceutical giants are actively deploying their cash towards mergers and acquisitions to accelerate growth and diversification. Sun Pharmaceutical Industries, the country’s largest drugmaker, recently acquired US-based Checkpoint Therapeutics for $355 million (approximately ₹3,064 crore), bolstering its portfolio in immuno-oncology and complex therapies. In a parallel move, Mankind Pharma announced a ₹13,768 crore acquisition of Bharat Serums, aiming to enhance its capabilities in biologics and women’s health.

Robust Financial Health Fuels Ambitious Expansion

Industry analysts note that many of these companies remain virtually debt-free and continue to generate strong operating cash flows. This financial strength enables them to pursue inorganic growth and innovation-led strategies while maintaining healthy profit margins in the 24–25% range.

However, there has been a noticeable uptick in selective borrowing. Net debt among the Nifty Pharma constituents rose to ₹11,782 crore as of March 2024 from ₹4,014 crore a year earlier—an indicator that companies are tapping into credit markets to fund capex and acquisitions while conserving their cash war chests for future strategic investments.

Shifting From Generics to Innovation

This evolving capital strategy reflects a broader transition from a generics-heavy business model to innovation-driven growth. Developing complex biologics and specialty therapies can demand upwards of $200 million in investment, requiring not only cash but long-term commitment. Sun Pharma is leading this transformation, with other key players like Zydus Lifesciences, Dr Reddy’s Laboratories, Lupin, and Alkem Laboratories also expanding into consumer health, diagnostics, and contract manufacturing services.

As global demand for advanced therapies grows and regulatory environments tighten, Indian pharma’s pivot towards high-value segments backed by strategic acquisitions signals a maturing industry preparing for its next phase of growth.